NCCN Guidelines® Insights - Gastrointestinal Stromal Tumors, Version 2.2022
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to speciﬁc tyrosine kinase inhibitors.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Gastrointestinal Stromal Tumors
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Gastrointestinal Stromal Tumors
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
John M. Kane III, MD, Panel Vice Chair
Mary Anne Bergman, Guidelines Coordinator, NCCN
Hema Sundar, PhD, Manager, Global Clinical Content, NCCN
Lisa E. Hang, PhD, Oncology Scientist/Medical Writer, NCCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Margaret von Mehren, MD, Panel Chair, has disclosed receiving grant/research support from Deciphera Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Cogent Biosciences, and Theseus Pharmaceuticals, Inc.; and serving as an advisor for Boehringer Ingelheim GmbH, Deciphera Pharmaceuticals, Inc., and GlaxoSmithKline.
Seth M. Pollack, MD, Panel Member, has disclosed serving as an advisor for Adaptimmune Therapeutics plc, Deciphera Pharmaceuticals, Inc., GlaxoSmithKline, Obsisian Therapeutics, Sensei Biotherapeutics, Inc., Springworks Therapeutics, and T-Knife GmbH; receiving grant/research support from Advenchen Laboratories, LLC, BioAtla, Inc., EMD Serono, Incyte Corporation, Obsisian Therapeutics, Rain Therapeutics, and TRACON Pharmaceuticals, Inc.; receiving consulting fees from Daiichi Sankyo, Inc., Deciphera Pharmaceuticals, Inc., Epizyme, Inc., Sensei Biotherapeutics, Inc., Springworks Therapeutics, and T-Knife GmbH; and serving in a product/speaker bureau for Deciphera Pharmaceuticals, Inc.
Richard F. Riedel, MD, Panel Member, has disclosed receiving grant/research support from Aadi Bioscience, Inc., AROG Pharmaceuticals, Inc., Ayala Pharmaceuticals, BioAtla, Inc., Cogent Biosciences, Inc., Daiichi-Sankyo Co., GlaxoSmithKline, Immune Design, Karyopharm Therapeutics, NanoCarrier Co., Ltd., Oncternal Therapeutics, Inc., Plexxikon, SpringWorks Therapeutics, TRACON Pharmaceuticals, Inc., and Trillium Therapeutics Inc.; and receiving consulting fees from Aadi Bioscience, Inc., Bayer HealthCare, Blueprint Medicines, Daiichi-Sankyo Co., Deciphera Pharmaceuticals, Inc., GlaxoSmithKline, NanoCarrier Co., Ltd., and SpringWorks Therapeutics.
Jason K. Sicklick, MD, Panel Member, has disclosed serving in a product/speakers’ bureau for Deciphera Pharmaceuticals, Inc., Foundation Medicine, Inc., La Hoffman-Roche, Merck & Co., Inc., and QED Therapeutics, Inc.; receiving grant/research support from Amgen, Inc. and Foundation Medicine, Inc.; and receiving consulting fees from Deciphera Pharmaceuticals, Inc. and Ethicon, Inc.
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-22-011-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 10, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation